CAREGEN CO.,LTD.

CAREGEN was founded in 2001 and listed on KOSDAQ in 2015 as a biotech company specializing in new drug development. Built on peptide and growth factor research, it produces professional therapy products such as fillers and mesotherapy items along with functional cosmetics, while developing a pipeline that includes the wet age-related macular degeneration candidate CG-P5 and the dry eye disease candidate CG-T1. The company has built a peptide library backed by more than 860 patents registered at home and abroad, sells its therapy products and functional cosmetics in 130 countries worldwide, and has completed a Phase 1 clinical trial for CG-P5 in the United States with Phase 2 in preparation.

CG-P5 · 습성 황반변성(wet AMD) · 임상 1상 완료, 임상 2상 준비중 · Peptide-based eye-drop candidate modulating the VEGF receptor pathway; Phase 1 results announced in the US in December 2025 showed signals related to reduced intraretinal fluid.

CG-T1 · 안구건조증 · 전임상 시험 진행중 · Peptide-based eye-drop candidate targeting the PAC1 receptor; preclinical studies showed efficacy signals such as increased tear secretion, with a clinical development strategy for FDA submission in preparation.

건성황반변성 치료제 · 건성황반변성 · 전임상시험 완료 · Eye-drop candidate that inhibits drusen formation via antioxidant activity and neovascularization suppression.

당뇨병성 망막병증 치료제 · 당뇨병성 망막병증 · 전임상시험 완료 · Inhibits VEGF receptor function to suppress neovascularization and vascular dilation.

다한증 치료제 · 다한증 · 인체적용시험 완료 · Early-stage program; mechanism and details undisclosed.

항바이러스 치료제 · COVID-19 · 임상 1상 완료 · Binds the SARS-CoV-2 spike protein to inhibit cell entry and improves symptoms via an anti-inflammatory effect.

근육강화 소재 · 근육 강화(노인성 근감소 개선) · 인체적용시험 완료, 2025년 2월 FDA NDI 허가 승인 · Health-functional-food ingredient promoting muscle fiber differentiation and regeneration.

혈당·비알콜성 지방간 개선 소재 · 혈당 감소, 비알콜성 지방간 · 인체적용시험 완료 · Ingredient reducing blood glucose via decreased insulin resistance and increased sensitivity; combination trials with metformin and ProGsterol ongoing.

고지혈증 개선 소재 · 콜레스테롤 감소 · 인체적용시험 완료 · Ingredient reducing cholesterol via inhibition of hepatic lipid synthesis and production.